Protagonist Therapeutics, Inc. (PTGX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Protagonist Therapeutics, Inc. ("Protagonist” or the "Company") (NASDAQ: PTGX). The investigation concerns whether Protagonist and certain of its officers and/or directors have violated federal securities laws.
On April 13, 2022, Protagonist disclosed in a filing with the U.S. Securities and Exchange Commission that "[t]he Company has received a letter from United States Food and Drug Administration (the "FDA") indicating the FDA's intent to rescind Breakthrough Therapy Designation for the Company's rusfertide product candidate in polycythemia vera," citing "observed malignancies[.]" Following this news, Protagonist's stock price fell $5.57 per share, or 21.83%, to close at $19.95 per share on April 14, 2022.
If you are aware of any facts relating to this investigation, or purchased Protagonist shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.